Gene Therapy Study Still Succeeding 3 Years Later

It has now been three years since a group of patients with severe hemophilia B, or factor IX (FIX) deficiency, in London received a single dose of gene therapy as part of a new clinical trial. Early results of the trial were positive as these patients began to generate FIX levels ranging from 1%-6%. Prior to the study, they produced little to none of the crucial clotting factor protein. – Click here to read more.